Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Cheng

Showing results (81-90 of 120) with videos related to

Pageof 12
Sort By:
JAMA|January 16, 2024
Nurse and Social Worker Palliative Telecare Team and Quality of Life in Patients With COPD, Heart Failure, or Interstitial Lung Disease: The ADAPT Randomized Clinical TrialDavid B Bekelman, William Feser, Brianne Morgan, et al.
Nature Medicine|June 3, 2008
Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanismsChristoph Buettner, Evan D Muse, Andrew Cheng, et al.
Emerging Microbes & Infections|June 8, 2017
Additional molecular testing of saliva specimens improves the detection of respiratory virusesKelvin Kw To, Lu Lu, Cyril Cy Yip, et al.
Annals of Internal Medicine|September 11, 2003
Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trialKathleen Squires, Anton L Pozniak, Gerald Pierone, et al.
JHEP Reports : Innovation in Hepatology|January 16, 2023
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosisStephen A Harrison, Peter J Ruane, Bradley Freilich, et al.
Nature Medicine|July 9, 2021
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trialStephen A Harrison, Peter J Ruane, Bradley L Freilich, et al.
The Lancet. HIV|June 22, 2018
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialJean-Michel Molina, Douglas Ward, Indira Brar, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 11, 2017
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 ResultsJosé R Arribas, Melanie Thompson, Paul E Sax, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 9, 2017
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed AdultsFrançois Raffi, Chloe Orkin, Amanda Clarke, et al.
Ebiomedicine|October 16, 2016
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir AlafenamideNicholas T Funderburg, Grace A McComsey, Manjusha Kulkarni, et al.
Pageof 12

Showing results (81-90 of 120) with videos related to

Sort By:
Pageof 12
JAMA|January 16, 2024
Nurse and Social Worker Palliative Telecare Team and Quality of Life in Patients With COPD, Heart Failure, or Interstitial Lung Disease: The ADAPT Randomized Clinical TrialDavid B Bekelman, William Feser, Brianne Morgan, et al.
Nature Medicine|June 3, 2008
Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanismsChristoph Buettner, Evan D Muse, Andrew Cheng, et al.
Emerging Microbes & Infections|June 8, 2017
Additional molecular testing of saliva specimens improves the detection of respiratory virusesKelvin Kw To, Lu Lu, Cyril Cy Yip, et al.
Annals of Internal Medicine|September 11, 2003
Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trialKathleen Squires, Anton L Pozniak, Gerald Pierone, et al.
JHEP Reports : Innovation in Hepatology|January 16, 2023
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosisStephen A Harrison, Peter J Ruane, Bradley Freilich, et al.
Nature Medicine|July 9, 2021
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trialStephen A Harrison, Peter J Ruane, Bradley L Freilich, et al.
The Lancet. HIV|June 22, 2018
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trialJean-Michel Molina, Douglas Ward, Indira Brar, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 11, 2017
Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 ResultsJosé R Arribas, Melanie Thompson, Paul E Sax, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 9, 2017
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed AdultsFrançois Raffi, Chloe Orkin, Amanda Clarke, et al.
Ebiomedicine|October 16, 2016
Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir AlafenamideNicholas T Funderburg, Grace A McComsey, Manjusha Kulkarni, et al.
Pageof 12